A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Inclusion Criteria:

Participants must meet all of the following criteria to be eligible for the study:

1. Voluntary participation and provision of signed written informed consent.
2. Age ≥ 18 years.
3. Life expectancy ≥ 3 months.
4. Histologically or cytologically confirmed diagnosis of Stage IIIB-IV lung cancer that is not amenable to curative surgery or radiotherapy.
5. Tumor demonstrates loss of BRG1 protein (encoded by the SMARCA4 gene) as confirmed by immunohistochemistry (IHC).
6. No prior systemic anti-cancer therapy for advanced disease.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
8. Willingness to provide archived or fresh tumor tissue samples from primary or metastatic lesions. If unavailable, enrollment may be permitted following investigator assessment.
9. At least one measurable lesion as defined by RECIST v1.1.
10. Adequate organ function within the screening period, as evidenced by:

10.1 Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L 10.2 Platelet count ≥ 100 × 10\^9/L 10.3 Hemoglobin ≥ 90 g/L (without transfusion within 14 days) 10.4 Serum creatinine ≤ 1 × ULN OR Creatinine clearance \> 50 mL/min (calculated by Cockcroft-Gault formula) 10.5 AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases) 10.6 Total bilirubin ≤ 1.5 × ULN (except for participants with Gilbert's syndrome) 10.7 TSH, FT3, and FT4 within normal limits (±10%)

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study:

1. Pathological diagnosis containing a small cell component.
2. Symptomatic brain metastases.
3. Leptomeningeal metastases.
4. Recurrence within 6 months after completing prior adjuvant therapy (if applicable).
5. Active, known, or suspected autoimmune disease (with specific exceptions, e.g., vitiligo, type I diabetes, hypothyroidism managed with hormone replacement only).
6. Active tuberculosis (TB) infection or history of active TB within the past year.
7. Comorbidities requiring immunosuppressive medications, including systemic corticosteroids at immunosuppressive doses.
8. Pregnancy or lactation in female participants.
9. Symptomatic interstitial lung disease that could interfere with the detection or management of suspected drug-related pulmonary toxicity.
10. Known HIV infection, active Hepatitis B (HBsAg positive with HBV-DNA \> 10\^3 copies/mL), or active Hepatitis C (HCV antibody positive with detectable HCV-RNA).
11. Significant history of neurological or psychiatric disorders.
12. Treatment with any investigational drug within 4 weeks prior to the first dose of study treatment.
13. Use of Chinese herbal medicines with anti-tumor activity within 2 weeks prior to study treatment initiation.
14. History of another active malignancy within the past 2 years (with specific exceptions for certain early-stage cancers).
15. Significant cardiovascular or cerebrovascular disease history.
16. Uncontrolled thrombotic events within 6 months prior to screening.
17. Administration of a live vaccine within 28 days prior to the first study dose.
18. Major surgery or significant trauma within 4 weeks prior to the first study dose.
19. Conditions that may impair oral drug absorption.
20. Uncontrolled active infection requiring systemic therapy.
21. Known hypersensitivity to any of the study drug components.
22. Any other condition that, in the investigator's judgment, would make the participant unsuitable for participation in the study.